Duke University patent applications published on July 11th, 2024

Summary of the patent applications from Duke University on July 11th, 2024

1. **Summary**: The recent patents filed by Duke University focus on innovative methods and technologies in the field of cancer treatment and genetic engineering. These patents include the use of methylation markers in the STING promoter for personalized cancer treatment decisions, splice-switching oligonucleotides for treating castrate-resistant prostate cancer, rationally-designed LAGLIDADG meganucleases for precise genetic modifications, and targeted transcriptional effectors derived from meganucleases for gene regulation. These inventions offer advancements in personalized medicine, targeted therapies, and gene editing techniques.

2. **Key Points of Patents**:

  * Methylation markers in the STING promoter for treatment decisions in cancer and tumors.
  * Splice-switching oligonucleotides to downregulate AR expression in castrate-resistant prostate cancer.
  * Rationally-designed LAGLIDADG meganucleases for precise genetic modifications.
  * Targeted transcriptional effectors derived from meganucleases for gene regulation.

3. **Notable Applications**:

  * Personalized treatment decisions for cancer patients.
  * Enhanced effectiveness of gene therapy and targeted cancer therapies.
  * Potential for commercialization in pharmaceutical industry and biotechnology research.
  * Advancements in precision medicine and gene therapy development.

Patent applications for Duke University on July 11th, 2024

VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONS (18277150)

Main Inventor

Soman Abraham

NON-IMMUNOGENIC POEGMA-APTAMER CONJUGATES (18277915)

Main Inventor

Ashutosh Chilkoti

Compositions For and Methods of Improving Gene Therapy (18547332)

Main Inventor

Aravind Asokan

COMPOSITIONS COMPRISING A VAGINAL MOLD AND METHODS OF USE THEREOF (18405331)

Main Inventor

Cassandra Kisby

Compositions and methods for improved malonyl-CoA biosynthesis using 2-stage dynamic metabolic control (18187102)

Main Inventor

Michael Lynch

FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS (18352037)

Main Inventor

Derek Jantz

RATIONALLY-DESIGNED MEGANUCLEASES WITH ALTERED SEQUENCE SPECIFICITY AND DNA-BINDING AFFINITY (18472881)

Main Inventor

James Jefferson Smith

SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE (18402154)

Main Inventor

Jennifer Freedman

METHYLATION MARKERS FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS (18548025)

Main Inventor

David ASHLEY